We plan to recruit 2,140 people into the RAUORA study. One in every three people enrolled in the study will be in the study for 24 weeks. Two in every three people enrolled will be in the study for a year.
If you agree to take part in the study, you will be randomly allocated (like the toss of a coin) to one of two groups:
- Tabex group: If you are in this group you will get a prescription for 12 weeks supply of cytisine tablets (Tabex). You’ll also be offered a choice of support services to give you advice and support to help you in your quit attempt.
- Champix group: If you are in this group you will get a prescription for a 12-week supply of varenicline tablets (Champix). You’ll also be offered a choice of support services to give you advice and support to help you in your quit attempt.
People in both groups will also receive four or five phone calls by a researcher during the study. The researcher will ask you some questions about the study medicine, your smoking and your health.
You will receive regular text messages to remind you about taking your medication, completing your electronic diary and reporting any side effects you may be experiencing.
If you’d like to know more about the study click here to read our participant information sheet. This sheet will tell you more about the trial, who can and can’t be involved, and what it involves.
If you’ve read the participant information sheet and are keen to join the trial please contact us.